Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

Ayoxxa Biosystems GmbH

AYOXXA Biosystems GmbH, an international The non-GMO plant breeding industry increasingly uses high-throughput DNA sequencing to arrive at new crop varieties faster and more efficiently. Computomics offers the cutting-edge bioinformatics analysis services required to efficiently use high-throughput sequencing data. Services include genome assembly and annotation, genomic variation, transcriptomics, epigenetics, metagenomics, genomic selection, and phenotyping. Sebastian J. Schultheiss, Managing Director at Computomics, describes the origin of the Computomics name: “We apply computational methods to a plethora of –omics data, like genomics and transcriptomics, so we came up with the name Comput-omics.” In addition to proven expertise and the delivery of stellar results, Computomics’ services feature independence from sequencing platforms and vendors, transparent processes and scientific reproducibility of all analyses. Computomics caters to an international market and already enables three of the top 10 seed companies to obtain their new products faster and more efficiently. With the investment, the company will foster its international expansion. “We are happy to join the company and the enthusiastic team. Sebastian and Tobias and their co-founders are internationally well-known experts in their field. With a strong customer base, we believe that Computomics has the potential to become a global player in ag biotech,” explains Ron Winkler, Senior Investmentmanager at HTGF. About Computomics GmbH Computomics is a spin-off of the University of Tübingen and the Max Planck Institute for Developmental Biology. Computomics was founded in 2012 when it became apparent that crop companies are interested in the cutting-edge bioinformatics analyses enabled by a breakthrough in DNA sequencing technology and by the scientific work of the founders. Four of the co-founders are accomplished scientists: Dr. Detlef Weigel is Director of the Molecular Biology Department of the Max Planck Institute for Developmental Biology, Dr. Daniel Huson is Professor for Algorithms in Bioinformatics at the University of Tübingen, Dr. Gunnar Rätsch is Professor for Biomedical Informatics at the ETH Zurich, Dr. Karsten Borgwardt is Professor for Data Mining in the Biosystems Department of the ETH in Basel. Co-founders Dr. Sebastian J. Schultheiss and Dr. Tobias Dezulian are scientists specialized on bioinformatics analyses of high-throughput DNA sequencing data. Both have had industry experience prior to founding and serve as Managing Directors of Computomics. Computomics has 10 employees and is based in Tübingen, Germany. Contact: Computomics GmbH Sebastian J. Schultheiss and Tobias Dezulian Christophstr. 32 72072 Tübingen Germany Phone: +49 7071 568 3995 info@computomics.com www.computomics.com About High-Tech Gruenderfonds High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II). Contact: High-Tech Gründerfonds Management GmbH Ron Winkler Schlegelstraße 2 53113 Bonn Phone: +49 (228) 823 001-00 Fax: +49 (228) 823 000-50 info@htgf.de www.high-tech-gruenderfonds.de [als ZUSATZINFO geholt via http://www.computomics.com/impressum.html ; ML] Impressum (Legal Information) Responsible for the content of this site: Computomics GmbH Christophstr. 32 72072 Tübingen Germany Commercial Register AG Stuttgart HRB742810, Place of Business Tübingen, Germany, VAT ID DE 286 347 612 Management: Dr. Tobias Dezulian E-mail: info@computomics.com Phone: +49 7071 568 3995 Website design & implementation: Liebchen+Liebchen Kommunikation GmbH biotech company based in Cologne (Germany), Boston (USA) and Singapore, has developed LUNARIS™ the proprietary technology platform for multiplex protein analysis. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple biomarkers in very small sample volume. Founded in 2010, AYOXXA is a biotech spin-off company of the National University of Singapore (NUS). Core to the cutting-edge technology is a bead-based method that yields 10,000-fold more data points than a standard immunoassay. LUNARIS™ was developed at Associate Professor Dieter Trau’s laboratory at the Department of Biomedical Engineering at NUS. In September 2015, AYOXXA launched LUNARIS™ 6-Plex Cytokine Kits to analyze prominent biomarkers that are important in inflammation and in immune regulation in human and mouse. Together with a sample volume down to 3 µL, an increased assay robustness, and using fluorescence readout, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development. *

 

Period Start 2011-12-16 established
  Group Ayoxxa (Group)
Products Industry In-situ Encoded Bead-based Arrays (IEBA)
  Industry 2 bead technology
Persons Person Schmidt, Andreas (Ayoxxa 201201– Managing Director of Ayoxxa Biosystems GmbH)
  Person 2 Richter, Andreas (Ayoxxa Biosystems 201501– CFO before Direvo Biotech + 4-Antibody)
     
Region Region Köln (Cologne)
  Country Germany
  Street 1 Nattermannallee
  City 50829 Köln
  Tel +49-221-222529-0
    Address record changed: 2012-09-28
     
Basic data Employees B: 11 to 50 (2016-10-03)
     
    * Document for �About Section�: Ayoxxa Biosystems GmbH. (9/14/15). "Press Release: Ayoxxa Biosystems Appoints Dr. Gerald Möller as Chairman of the Board". Cologne.
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Ayoxxa (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top